Symmetry Partners LLC Has $397,000 Stake in Hologic, Inc. (NASDAQ:HOLX)

Symmetry Partners LLC trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLXFree Report) by 12.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,573 shares of the medical equipment provider’s stock after selling 782 shares during the quarter. Symmetry Partners LLC’s holdings in Hologic were worth $397,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in Hologic by 5.1% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 33,448 shares of the medical equipment provider’s stock worth $2,569,000 after purchasing an additional 1,631 shares during the last quarter. LSV Asset Management increased its position in Hologic by 307.5% in the 1st quarter. LSV Asset Management now owns 37,900 shares of the medical equipment provider’s stock worth $2,911,000 after buying an additional 28,600 shares during the period. Raymond James Trust N.A. increased its position in Hologic by 7.4% in the 1st quarter. Raymond James Trust N.A. now owns 6,875 shares of the medical equipment provider’s stock worth $528,000 after buying an additional 476 shares during the period. Dimensional Fund Advisors LP increased its position in Hologic by 4.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,305,399 shares of the medical equipment provider’s stock worth $177,098,000 after buying an additional 106,315 shares during the period. Finally, Aviva PLC increased its position in Hologic by 0.7% in the 1st quarter. Aviva PLC now owns 75,543 shares of the medical equipment provider’s stock worth $5,803,000 after buying an additional 513 shares during the period. 92.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Hologic

In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of the stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the transaction, the director now owns 1,572 shares of the company’s stock, valued at $119,802.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of the stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the sale, the director now directly owns 1,572 shares in the company, valued at $119,802.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Karleen Marie Oberton sold 14,940 shares of the stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $75.00, for a total value of $1,120,500.00. Following the completion of the sale, the chief financial officer now owns 103,916 shares of the company’s stock, valued at $7,793,700. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 32,846 shares of company stock valued at $2,473,443. 1.75% of the stock is currently owned by company insiders.

Hologic Price Performance

Hologic stock opened at $75.91 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.18 and a current ratio of 3.89. The firm has a market cap of $17.82 billion, a P/E ratio of 35.98, a P/E/G ratio of 2.58 and a beta of 1.00. The business’s fifty day moving average is $74.11 and its two-hundred day moving average is $71.78. Hologic, Inc. has a 52 week low of $64.02 and a 52 week high of $87.88.

Hologic (NASDAQ:HOLXGet Free Report) last posted its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.03. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $989.32 million. During the same quarter in the previous year, the firm earned $1.07 earnings per share. The business’s revenue was down 5.7% on a year-over-year basis. Equities research analysts forecast that Hologic, Inc. will post 4.02 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on HOLX. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research report on Friday, February 2nd. StockNews.com cut Hologic from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. Raymond James boosted their price objective on Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd. UBS Group boosted their price objective on Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a research report on Friday, February 2nd. Finally, Needham & Company LLC boosted their price objective on Hologic from $83.00 to $90.00 and gave the company a “buy” rating in a research report on Friday, February 2nd. Six equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $86.89.

Check Out Our Latest Report on Hologic

Hologic Profile

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Read More

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.